JATT II Acquisition Corp. (JATT) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
We are a blank check company incorporated on January 13, 2026, as a Cayman Islands exempted company with limited liability for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any potential business combination target with respect to our initial business combination. While we may pursue an initial business combination in any business or industry, we intend to focus our search on healthcare and healthcare-related businesses, with a primary emphasis on biotechnology and broader life sciences. In particular, we intend to seek businesses that can benefit from the clinical, scientific, operational, strategic and capital markets experience of our management team and board of directors and, in many cases, from access to the public markets as a means of funding continued development, executing strategic transactions and increasing visibility with investors and potential partners. We expect to focus particularly, though not exclusively, on businesses applying data-driven approaches, including machine learning, computational biology, structure-based drug design and related technologies, to improve the therapeutic discovery and development process. --- Our management team is led by Dr. Someit Sidhu, our Chairman and Chief Executive Officer, and Mr. Nicholas Fernandez, our Chief Financial Officer, each of whom has significant experience building, operating and investing in the life sciences and medical technology sectors globally. They will be supported by a team of investment professionals and support resources as further described below. We believe our management team has complementary skills and experience relevant to our business strategy, as well as significant expertise in identifying high quality companies seeking financing as a stepping stone to public markets. With significant exposure to such opportunities and deep experience in investing in both private and public life science markets, we expect to have access to a large volume of potential investment opportunities, which we believe represents a competitive advantage. Our executive offices are located at 153 Central Avenue, C/O 56, Westfield, NJ.
JATT II Acquisition Corp.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Blank Checks
No case yet. It builds on the next filing, report or 13F period.
High 12.75 at 1:15 pm ET, low 12.12 at 2:00 pm ET.
JATT II Acquisition Corp. has no measured co-movers clearing our correlation floor, so only its SEC classification is shown.
SIC 6770, Blank Checks, from each company's own filings. Largest first.
JATT (JATT II Acquisition Corp.) has 0 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
each tick is a filing
25 managers report a position worth $61.7M between them, and 12 of them hold 80% of it.